glp-1 anti-obesity Chart: 1 in 8 Americans Now Use Drugs for Weight Loss Weight Reduction with GLP-1 Agonists

Amid the Biden administrations recent proposal to expand obesity drug coverage under Medicare and Medicaid, experts at Real Chemistry examined which state Medicaid programs currently cover GLP-1s approved to treat obesity and how much they are spending

While ensuring proper temperature requirements and safety of the shipment is paramount, the convenience offered to patients is also significant

May 19, 2024: Novo Nordisk and Eli Lilly Outline Legal Strategy to Reduce Liability and Challenge Plaintiff Claims on Ozempic and Mounjaro Novo Nordisk and Eli Lilly recently outlined their strategy in a defendant statement to reduce liability and minimize plaintiff recoveries

Germany is expected to grow at a CAGR of 6.6%, supported by an increasing diabetic population, a well-established healthcare system, and the adoption of advanced therapeutic solutions for managing diabetes